Literature DB >> 32279993

A missense mutation of Leu74Pro of OGR1 found in familial amelogenesis imperfecta actually causes the loss of the pH-sensing mechanism.

Koichi Sato1, Chihiro Mogi2, Alan J Mighell3, Fumikazu Okajima4.   

Abstract

Ovarian cancer G protein-coupled receptor 1 (OGR1), also known as GPR68, is a proton-sensing G protein-coupled receptor (GPCR) coupling to Gq/11/phospholipase C/Ca2+ signaling pathways. The specific histidine residues at the extracellular surface of OGR1 are suggested to be involved in the proton sensing. Later, some metal ions, including nickel ion (Ni2+), are also indicated to be OGR1 ligands. OGR1 polymorphic variants have recently been found in three families with amelogenesis imperfecta, which suggested that OGR1 is required for the process of dental enamel formation. One of these families possesses a missense mutation from leucine to proline at 74 (L74P) of OGR1. In the present study, we characterized HEK293 cells with L74P OGR1 (L74P-OGR1) and hemagglutinin (HA)-tag, as compared with cells with wild-type OGR1 (WT-OGR1) and HA-tag. We found that either acidic pH or NiCl2 induced intracellular Ca2+ mobilization and morphological change in WT-OGR1-transfected cells; however, the extracellular stimulus-induced actions were severely damaged in L74P-OGR1-transfected cells. We further confirmed that either WT-OGR1 or L74P-OGR1 is localized mainly in the surface of the cells, but only WT-OGR1 is internalized in response to acidification or NiCl2. Thus, the L74P-OGR1 protein may be distributed in the plasma membranes but severely damaged in the receptor functions. We speculate that L74P in the second transmembrane domain in OGR1 may result in conformational changes in the receptor, thereby disturbing the sensing extracellular signals, i.e., protons or metal ions, and/or transducing them to the intracellular signaling machinery through G proteins.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Extracellular acidification; G protein-coupled receptor; Intracellular Ca(2+); Missense variant; OGR1

Year:  2020        PMID: 32279993     DOI: 10.1016/j.bbrc.2020.04.005

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines.

Authors:  Riya Khetan; Cintya Dharmayanti; Todd A Gillam; Eric Kübler; Manuela Klingler-Hoffmann; Carmela Ricciardelli; Martin K Oehler; Anton Blencowe; Sanjay Garg; Hugo Albrecht
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

Review 2.  From Pinocytosis to Methuosis-Fluid Consumption as a Risk Factor for Cell Death.

Authors:  Markus Ritter; Nikolaus Bresgen; Hubert H Kerschbaum
Journal:  Front Cell Dev Biol       Date:  2021-06-23

Review 3.  Physiological relevance of proton-activated GPCRs.

Authors:  Pedro H Imenez Silva; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2022-03-05       Impact factor: 3.657

4.  Identification of the C-terminal region in Amelogenesis Imperfecta causative protein WDR72 required for Golgi localization.

Authors:  Dina Husein; Ahmed Alamoudi; Yoshio Ohyama; Hanna Mochida; Brigitte Ritter; Yoshiyuki Mochida
Journal:  Sci Rep       Date:  2022-03-17       Impact factor: 4.379

5.  Novel Mutations in GPR68 and SLC24A4 Cause Hypomaturation Amelogenesis Imperfecta.

Authors:  Figen Seymen; Hong Zhang; Yelda Kasimoglu; Mine Koruyucu; James P Simmer; Jan C-C Hu; Jung-Wook Kim
Journal:  J Pers Med       Date:  2021-12-28

6.  Metal-Stimulated Interleukin-6 Production Through a Proton-Sensing Receptor, Ovarian Cancer G Protein-Coupled Receptor 1, in Human Bronchial Smooth Muscle Cells: A Response Inhibited by Dexamethasone.

Authors:  Maiko Kadowaki; Koichi Sato; Hisashi Kamio; Makoto Kumagai; Rikishi Sato; Takafumi Nyui; Yukihiro Umeda; Yuko Waseda; Masaki Anzai; Haruka Aoki-Saito; Yasuhiko Koga; Takeshi Hisada; Hideaki Tomura; Fumikazu Okajima; Tamotsu Ishizuka
Journal:  J Inflamm Res       Date:  2021-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.